Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
Subtype Selective Phosphodiesterase 4 (PDE4) Inhibitors for the Treatment of Chronic Obstructive Pulmonary Diesease
Health Technologies at Strathclyde United Kingdom flag United Kingdom
Abstract ID:
Using a novel screening approach, researchers at Strathclyde have identified subtype selective PDE4 inhibitors....
Contact
Participants
You
Email me a copy of this message

Background


Chronic Obstructive Pulmonary Disease (COPD)is a severely disabling lung illness and is currently the fourth most common cause of death worldwide. Available therapeutics mostly target symptom relief, leaving a strong need for new, disease-targeted medications.?


Technology


Using a novel screening approach, researchers at Strathclyde have identified subtype selective Phosphodiesterase 4 (PDE4)? inhibitors. These are being optimised with the aim of delivering 'best in class' therapeutics to reduce the destructive lung inflammation that characterises COPD.


Key Benefits


Predicted superior efficacy and safety over current therapies.


Potential to slow or halt disease progression.


Improved tolerability compared to 'global' PDE4 inhibitors?.


Markets and Applications


COPD has a high average incidence rate of 8.1% in the general population of the seven major pharmaceutical markets, with the global COPD market projected to reach $14bn per year by 2014 and continue to expand through a combination of increasing incidence and improved screening and diagnosis.

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought

Patent applications will be filed upon identification of strong lead candidates. Funding will then be sought for formation of a University of Strathclyde spin-out company to create additional value through identification and profiling of preclinical drug candidates for partnership or sale.

FEATURED
Last Updated Oct 2014
Technology Type
Phase of Development EARLY STAGE
UNIVERSITY